hVIVO (LON:HVO) Trading Up 10.3% - Time to Buy?

Key Points

• hVIVO shares jumped 10.3% to GBX 8.17 (intraday high GBX 8.18) on Tuesday, with roughly 1,095,579 shares traded—about 66% below its average daily volume—and a prior close of GBX 7.40.
• Analyst sentiment is positive: Shore Capital reissued a Buy rating with a GBX 25 target, and the stock has two Buy ratings with an average target price of GBX 17.50.
• hVIVO is a pharmaceutical contract research company specializing in human challenge clinical trials; it has a market cap of £53.7M, a P/E of 10.13, a current ratio of 1.60 and a debt-to-equity ratio of 33.7.

hVIVO plc (LON:HVO - Get Free Report) was up 10.3% during trading on Tuesday . The company traded as high as GBX 8.18 and last traded at GBX 8.17. Approximately 1,095,579 shares changed hands during trading, a decline of 66% from the average daily volume of 3,212,935 shares. The stock had previously closed at GBX 7.40.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reissued a "buy" rating and set a GBX 25 target price on shares of hVIVO in a research report on Thursday, January 29th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of GBX 17.50.

hVIVO Stock Up 5.4%

The business's 50-day simple moving average is GBX 7.61 and its 200 day simple moving average is GBX 6.79. The company has a current ratio of 1.60, a quick ratio of 1.16 and a debt-to-equity ratio of 33.70. The firm has a market cap of £53.70 million, a PE ratio of 10.13 and a beta of 1.67.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.